Oncoscience Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

Oncoscience General Information

Description

Developer of biopharmaceutical drugs intended to focus on the treatment of orphan indications in oncology. The company offers therapeutic options that can be used for the treatment of several malignancies, thereby enabling its clients to be provided with products that serve as an adequate treatment of these orphan diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Osterbrooksweg 59
  • 22869 Schenefeld
  • Germany
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • Osterbrooksweg 59
  • 22869 Schenefeld
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncoscience Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncoscience‘s full profile, request access.

Request a free trial

Oncoscience Patents

Oncoscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016299368-A1 Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) Active 27-Jul-2015
AU-2016299368-B2 Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) Active 27-Jul-2015
CA-2992375-A1 Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) Pending 27-Jul-2015
EP-3328426-A1 Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) Active 27-Jul-2015
EP-3328426-B8 Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using monoclonal antibodies against the epidermal growth factor receptor (egfr) Active 27-Jul-2015 A61K39/395
To view Oncoscience’s complete patent history, request access »

Oncoscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncoscience FAQs

  • When was Oncoscience founded?

    Oncoscience was founded in 2001.

  • Where is Oncoscience headquartered?

    Oncoscience is headquartered in Schenefeld, Germany.

  • What is the size of Oncoscience?

    Oncoscience has 4 total employees.

  • What industry is Oncoscience in?

    Oncoscience’s primary industry is Biotechnology.

  • Is Oncoscience a private or public company?

    Oncoscience is a Private company.

  • What is Oncoscience’s current revenue?

    The current revenue for Oncoscience is .

  • When was Oncoscience acquired?

    Oncoscience was acquired on 16-Jul-2015.

  • Who acquired Oncoscience?

    Oncoscience was acquired by Innokeys.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process